{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:09:56Z","timestamp":1790237396951,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10637-026-01602-6","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:39:58Z","timestamp":1770903598000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma"],"prefix":"10.1007","volume":"44","author":[{"given":"Fen","family":"Saj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios S.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"1602_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI et al (2021) Cholangiocarcinoma. Nat Rev Dis Primers 7:65","journal-title":"Nat Rev Dis Primers"},{"key":"1602_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L et al (2023) Cholangiocarcinoma \u2014 novel biological insights and therapeutic strategies. Nat Rev Clin Oncol 20:470\u2013486","journal-title":"Nat Rev Clin Oncol"},{"key":"1602_CR3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","volume":"10","author":"AN Boscoe","year":"2019","unstructured":"Boscoe AN, Rolland C, Kelley RK (2019) Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol 10:751\u2013765","journal-title":"J Gastrointest Oncol"},{"key":"1602_CR4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","volume":"127","author":"O Neumann","year":"2022","unstructured":"Neumann O, Burn TC, Allg\u00e4uer M et al (2022) Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. Br J Cancer 127:1540\u20131549","journal-title":"Br J Cancer"},{"key":"1602_CR5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21:796\u2013807","journal-title":"Lancet Oncol"},{"key":"1602_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21:671\u2013684","journal-title":"Lancet Oncol"},{"key":"1602_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1:EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"1602_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865","journal-title":"Lancet"},{"key":"1602_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJMoa2510308","volume":"394","author":"PA J\u00e4nne","year":"2026","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K et al (2026) Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 394:27\u201338","journal-title":"N Engl J Med"},{"key":"1602_CR10","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","volume":"392","author":"E Elez","year":"2025","unstructured":"Elez E, Yoshino T, Shen L et al (2025) Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer. N Engl J Med 392:2425\u20132437","journal-title":"N Engl J Med"},{"key":"1602_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u201381","journal-title":"N Engl J Med"},{"key":"1602_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1158\/1535-7163.MCT-23-0460","volume":"23","author":"CL Lee","year":"2024","unstructured":"Lee CL, O\u2019Kane GM, Mason WP et al (2024) Circulating oncometabolite 2-hydroxyglutarate as a potential biomarker for isocitrate dehydrogenase (IDH1\/2) mutant cholangiocarcinoma. Mol Cancer Ther 23:394\u2013399","journal-title":"Mol Cancer Ther"},{"key":"1602_CR13","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","volume":"32","author":"TS Bekaii-Saab","year":"2021","unstructured":"Bekaii-Saab TS, Bridgewater J, Normanno N (2021) Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol 32:1111\u20131126","journal-title":"Ann Oncol"},{"key":"1602_CR14","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y et al (2023) Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 389:1935\u20131948","journal-title":"N Engl J Med"},{"key":"1602_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","volume":"4","author":"MA Lowery","year":"2019","unstructured":"Lowery MA, Burris HA 3rd, Janku F et al (2019) Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol 4:711\u2013720","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1602_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204","volume":"4","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Verstovsek S (2023) Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med 4:101204","journal-title":"Cell Rep Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01602-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:53:52Z","timestamp":1777294432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01602-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01602-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Has the study been presented in part elsewhere"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimers"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}